Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C

被引:3
|
作者
Posada-Cespedes, Susana [1 ,2 ]
Van Zyl, Gert [3 ,4 ]
Montazeri, Hesam [5 ]
Kuipers, Jack [1 ,2 ]
Rhee, Soo-Yon [6 ]
Kouyos, Roger [7 ,8 ,9 ]
Guenthard, Huldrych F. [7 ,8 ,9 ]
Beerenwinkel, Niko [1 ,2 ]
机构
[1] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, Basel, Switzerland
[2] SIB Swiss Inst Bioinformat, Basel, Switzerland
[3] Stellenbosch Univ, Fac Med & Hlth Sci, Div Med Virol, Cape Town, South Africa
[4] Natl Hlth Lab Serv, Cape Town, South Africa
[5] Univ Tehran, Inst Biochem & Biophys, Dept Bioinformat, Tehran, Iran
[6] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[7] Univ Hosp Zurich, Div Infect Dis, Zurich, Switzerland
[8] Univ Hosp Zurich, Hosp Epidemiol, Zurich, Switzerland
[9] Univ Zurich, Inst Med Virol, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
CANCER PROGRESSION MODELS; DRUG-RESISTANCE; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; EVOLUTIONARY PATHWAYS; PROTEASE; PATTERNS; DIVERSITY; EMERGENCE; SEQUENCES;
D O I
10.1371/journal.pcbi.1008363
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Author summary There is a disparity in the distribution of infections by HIV-1 subtype in the world. Subtype B is predominant in America, Australia and western and central Europe, and most therapeutic strategies are based on research and clinical studies on this subtype. However, non-B subtypes represent the majority of global HIV-1 infections; e.g., subtype C alone accounts for nearly half of all HIV-1 infections. We present a statistical framework enabling the comparison of patterns of accumulating mutations in different HIV-1 subtypes. Specifically, we compare the temporal ordering of lopinavir resistance mutations in HIV-1 subtypes B versus C. To this end, we combine the Hidden Conjunctive Bayesian Network (H-CBN) model with an approximate inference scheme enabling comparisons of larger networks. We show that the development of resistance to lopinavir differs significantly between subtypes B and C, such that findings based on subtype B sequences can not always be applied to sybtype C. The described methodology is suitable for comparing different subgroups in the context of other evolutionary processes. Although combination antiretroviral therapies seem to be effective at controlling HIV-1 infections regardless of the viral subtype, there is increasing evidence for subtype-specific drug resistance mutations. The order and rates at which resistance mutations accumulate in different subtypes also remain poorly understood. Most of this knowledge is derived from studies of subtype B genotypes, despite not being the most abundant subtype worldwide. Here, we present a methodology for the comparison of mutational networks in different HIV-1 subtypes, based on Hidden Conjunctive Bayesian Networks (H-CBN), a probabilistic model for inferring mutational networks from cross-sectional genotype data. We introduce a Monte Carlo sampling scheme for learning H-CBN models for a larger number of resistance mutations and develop a statistical test to assess differences in the inferred mutational networks between two groups. We apply this method to infer the temporal progression of mutations conferring resistance to the protease inhibitor lopinavir in a large cross-sectional cohort of HIV-1 subtype C genotypes from South Africa, as well as to a data set of subtype B genotypes obtained from the Stanford HIV Drug Resistance Database and the Swiss HIV Cohort Study. We find strong support for different initial mutational events in the protease, namely at residue 46 in subtype B and at residue 82 in subtype C. The inferred mutational networks for subtype B versus C are significantly different sharing only five constraints on the order of accumulating mutations with mutation at residue 54 as the parental event. The results also suggest that mutations can accumulate along various alternative paths within subtypes, as opposed to a unique total temporal ordering. Beyond HIV drug resistance, the statistical methodology is applicable more generally for the comparison of inferred mutational networks between any two groups.
引用
收藏
页数:25
相关论文
共 50 条
  • [21] Molecular characterization of full-length Tat in HIV-1 subtypes B and C
    Roy, Chandra Nath
    Khandaker, Irona
    Furuse, Yuki
    Oshitani, Hitoshi
    BIOINFORMATION, 2015, 11 (03) : 151 - 160
  • [22] Mutations in HIV-1 protease associated with resistance to amprenavir contribute towards phenotypic resistance to lopinavir
    Parkin, NT
    Chappey, C
    Petropoulos, CJ
    ANTIVIRAL THERAPY, 2002, 7 : S29 - S29
  • [23] HIV-1 genetic subtypes and antiretroviral therapy resistance testing
    Galpin, S
    Beddows, S
    Johargy, A
    Ashraf, A
    Prater, AJ
    White, N
    Clarke, J
    McClure, M
    Weber, JN
    AIDS, 2000, 14 : S118 - S118
  • [24] Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study
    Shadrina, O. A.
    Zatsepin, T. S.
    Agapkina, Yu. Yu.
    Isaguliants, M. G.
    Gottikh, M. B.
    ACTA NATURAE, 2015, 7 (01): : 78 - 86
  • [25] Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D
    Church, Jessica D.
    Jones, Dana
    Flys, Tamara
    Hoover, Donald
    Marlowe, Natalia
    Chen, Shu
    Shi, Chanjuan
    Eshleman, James R.
    Guay, Laura A.
    Jackson, J. Brooks
    Kumwenda, Newton
    Taha, E. Taha
    Eshleman, Susan H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2006, 8 (04): : 430 - 432
  • [26] Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G
    Deforche, K
    Camacho, R
    Grossman, Z
    Silander, T
    Soares, M
    Shafer, RW
    Van Laethem, K
    Carvalho, AP
    Wynhoven, B
    Cane, P
    Clarke, J
    Snoeck, J
    Sirivichayakul, S
    Ariyoshi, K
    Holguin, A
    Rudich, H
    Rodrigues, R
    Bouzas, M
    Brun-Vézinet, F
    Cahn, P
    Brigido, LF
    Soriano, V
    Sugiura, W
    Phanuphak, P
    Morris, L
    Weber, J
    Pillay, D
    Tanuri, A
    Harrigan, PR
    Schapiro, JM
    Katzenstein, D
    Kantor, R
    Vandamme, AM
    ANTIVIRAL THERAPY, 2005, 10 : S132 - S132
  • [27] Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G
    Deforche, K
    Camacho, R
    Grossman, Z
    Silander, T
    Soares, MA
    Shafer, RW
    Van Laethem, K
    Carvalho, AP
    Wynhoven, B
    Cane, P
    Clarke, J
    Snoeck, J
    Sirivichayakul, S
    Ariyoshi, K
    Holguin, A
    Rudich, H
    Rodrigues, R
    Bouzas, MB
    Brun-Vézinet, F
    Cahn, P
    Brigido, LF
    Soriano, V
    Sugiura, W
    Phanuphak, P
    Morris, L
    Weber, J
    Pillay, D
    Tanuri, A
    Harrigan, PR
    Schapiro, JM
    Katzenstein, D
    Kantor, R
    Vandamme, AM
    ANTIVIRAL THERAPY, 2005, 10 (04) : S132 - S132
  • [28] GENETIC SUBTYPES OF HIV-1
    LOUWAGIE, J
    MCCUTCHAN, F
    MASCOLA, J
    EDDY, G
    FRANSEN, K
    PEETERS, M
    VANDERGROEN, G
    BURKE, D
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 : S147 - S150
  • [29] HIV-1 subtypes in Yugoslavia
    Stanojevic, M
    Papa, A
    Papadimitriou, E
    Zerjav, S
    Jevtovic, D
    Salemovic, D
    Jovanovic, T
    Antoniadis, A
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (07) : 519 - 522
  • [30] HIV-1 subtypes in Denmark
    Machuca, R
    Bogh, M
    Salminen, M
    Gerstoft, J
    Kvinesdal, B
    Pedersen, C
    Obel, N
    Nielsen, H
    Nielsen, C
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2001, 33 (09) : 697 - 701